Skip to main content
Premium Trial:

Request an Annual Quote

Bruce York, Philip Ranker

Premium
Nastech Pharmaceutical has appointed Bruce York to the position of secretary and interim CFO.
 
York replaces Philip Ranker, who resigned as secretary and CFO last week.
 
York most recently served as senior director of finance and chief accounting officer for Nastech. He also currently serves as CFO of Nastech’s RNA drugs spinout MDRNA.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.